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Background: As the population ages, an increasing number of acute medical patients will 
be older and have comorbidities that may interact with their primary admission condition and 
worsen their prognosis.
Objectives: To examine whether 6-month mortality following acute medical admission was 
associated with gender, age, or comorbidity.
Methods: We used the Danish National Patient Registry, covering all Danish hospitals, to 
identify all acute medical admissions to Aarhus University Hospital during 2008 and comor-
bidities. We obtained mortality data from the Danish Civil Registration System. We computed 
mortality risks and hazard ratios with 95% confidence intervals (CIs) for gender, age, and 
comorbidity groups.
Results: We identified 3,727 patients (53.6% women) with a median age of 63 years for women 
and 60 years for men. The overall 6-month mortality rate was 12.8%. The adjusted hazard ratio 
was 2.77 (95% CI, 2.11–3.64) for patients aged 65–80 years and 5.25 (95% CI, 4.06–6.80) for 
patients older than 80 years, compared with patients younger than 65 years. The adjusted hazard 
ratio was 2.43 (95% CI, 1.82–3.24) and 3.87 (95% CI, 2.91–5.15) for patients with moderate 
and high comorbidity, respectively, compared with low comorbidity.
Conclusion: Age and comorbidity were important predictors of mortality after acute medical 
admission.
Keywords: cohort study, comorbidity, epidemiology, hospital admission, internal medicine, 
prognosis, registries
Introduction
The aging population and the increasing prevalence of chronic conditions present 
major public health challenges.1,2 The western population aged 65 years and older is 
projected to increase from approximately 15% in 2010 to 25% by 2040.1,3 The most 
rapid growth will occur in age groups older than 80 years.1 Approximately 45% of the 
general population and 88% of the population older than 65 years have at least one 
chronic disease.2 The vast majority of western health-care expenditures are already 
related to treatment of chronic conditions.4 The increasing proportion of elderly 
people is expected to increase the general need for hospitalization.2 Moreover, these 
  hospitalizations will involve patients with comorbidities along with their primary 
admission condition. Thus, the future burden of comorbidity requiring medical   attention 
will further increase health-care expenditures.1,2
Identifying prognostic factors for acute medical diseases is essential in the plan-
ning of health-care needs, evaluation of effectiveness of hospital care, and prevention Clinical Epidemiology 2010:2 submit your manuscript | www.dovepress.com
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of posthospital death. Previous studies of acute medical 
patients’ prognoses have focused entirely on the index 
condition.5 Therefore, we conducted a feasibility study to 
examine the 6-month mortality following acute medical 
admission in Denmark and whether it was associated with 
gender, age, or comorbidity level. Furthermore, we aimed 
at describing the potential of the present study design for 
prognostic research on patients who were admitted acutely 
to internal medical departments.
Methods
Setting
We conducted this population-based cohort study in the 
  Aarhus city area (population, 300,000) using data from 
  Danish National Registries. The Danish National Health 
Service provides universal tax-supported health care, 
guaranteeing unfettered access to general practitioners and 
hospitals, and partial reimbursement for prescribed medica-
tions. Unambiguous linkage between all Danish registries 
is possible using the unique 10-digit central personal regis-
try number assigned to each Danish citizen at birth and to 
  residents upon immigration.6
Patients
The Danish National Patient Registry (DNPR) covers 
all Danish hospitals and contains data on the admitting 
departments, admission priorities, dates of admission and 
discharge, and all primary and secondary discharge diag-
noses from nonpsychiatric hospitals since 1977 and from 
emergency room and outpatient clinic visits since 1995.7 
Each discharge is associated with 1 primary diagnosis and 
1 or more   secondary diagnoses classified according to the 
International Classification of Diseases, Eighth Revision 
(ICD-8) until the end of 1993 and, thereafter, International 
Classification of Diseases, Tenth Revision (ICD-10).7 We 
were interested in identifying medical patients only, distinct 
from surgical or psychiatric patients. All patients admitted 
to a medical admission unit (MAU) in Denmark are regis-
tered with a unique department code at the time of arrival, 
independently of later transfers to other departments. Using 
the DNPR, we identified patients with a first-ever acute 
admission to the MAU at Aarhus University Hospital, 
  Nørrebrogade (code: 7003.071), between January 1, 2008, 
and December 31, 2008. This unit provides acute medical 
care for half of the Aarhus city population. The residence 
address determines to which hospital patients are referred. 
Codes for admission priorities registered independently in the 
DNPR confirmed that all patients identified were admitted 
acutely (code: ATA1). We defined the primary admission 
condition as the index condition and the date of admission 
as the index date. Per   protocol, we excluded patients with a 
pregnancy-related index condition (n = 0), patients younger 
than 18 years (n = 83), and patients with missing records of 
vital statistics (primarily non-Danish citizens; n = 23). All 
types of medical patients are admitted to the MAU except 
patients with acute myocardial infarction or stroke, who 
are directly admitted to specialized departments. Patient 
admissions last until transfer to another hospital department, 
discharge, or in-hospital death.
Mortality
We obtained all-cause mortality from the Danish Civil 
  Registration System.8 This registry is updated daily and 
contains vital statistics – including date of birth, change of 
address, date of emigration, and exact date of death – on the 
Danish population since 1968.8
Comorbidity
We searched the DNPR for inpatient and outpatient diag-
noses for patient comorbidities before the index date.9 We 
categorized patients’ comorbidity burden using Charlson 
comorbidity index (CCI).10 The CCI is a validated method 
of classifying comorbidity to predict short-term and long-
term mortality taking into consideration both the number 
and seriousness of diseases.11–13 In the CCI, a number 
of conditions are assigned weights of 1, 2, 3, or 6. The 
weights are allocated as follows: 1 – myocardial infarc-
tion, congestive heart failure, peripheral vascular disease, 
stroke,   dementia, chronic pulmonary disease, connective 
tissue disease, ulcer disease, mild liver disease, or diabetes 
mellitus; 2 –   hemiplegia, moderate or severe renal disease, 
diabetes with complications, any tumor, leukemia, or lym-
phoma; 3 – moderate to severe liver disease; 6 – metastatic 
solid tumor or AIDS. The Charlson index score is the total 
of the assigned weights, and thus represents a measure of the 
overall comorbidity burden.10 Three levels of comorbidity 
were defined based on Charlson index scores of 0 (low), 
1–2 (moderate), and 3 or more (high).14 The ICD codes for 
each of the conditions included in the CCI are provided in 
the Appendix.
Statistical analysis
We characterized the patients according to gender, age, 
comorbidity, and index condition. Patients were followed 
from index date until the date of death, emigration, or comple-
tion of 6 months of follow-up, whichever came first.Clinical Epidemiology 2010:2 submit your manuscript | www.dovepress.com
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Using the Kaplan–Meier estimator, we plotted a 6-month 
overall mortality curve and calculated the cumulative 1-, 3-, 
and 6-month mortality risks, overall and stratified on gender, 
age, and comorbidity groups. The covariates eligible for 
inclusion in the model as potential confounders were gender, 
age as a continuous variable, and comorbidity level. Using 
the average covariate method,15 we adjusted the mortality 
curves for these covariates.
Using Cox proportional hazards regression model, we 
calculated mortality hazard ratios (HRs) with 95% confidence 
intervals (CIs) comparing mortality rates within gender, age, 
and comorbidity groups. For each group, the category with the 
lowest mortality rate was set as reference, ie, female gender, 
age 18–64 years, and low comorbidity level, respectively. To 
examine any interaction between covariates, we performed 
stratified analyses on all 3 covariates. In the overall analysis, 
we adjusted for the other 2 covariates. In the stratified analysis, 
we adjusted for the remaining covariate only, except within 
age strata where additional adjustment for age as a continuous 
variable was made to reduce residual confounding. Analyses 
were performed using Statistical Analysis System (SAS) 
  version 9.2 (SAS Institute Inc, Cary, North Carolina, USA).
Results
Patient characteristics
We identified 3,727 adult patients with a first-ever acute hos-
pital admission during 2008 to the MAU at Aarhus University 
Hospital, Nørrebrogade. Patient characteristics are presented in 
Table 1. Slightly more than half of these patients were female 
(53.6%). At index date, 2,045 (54.9%) patients were younger 
than 65 years, 886 (23.8%) were aged between 65 and 80 years, 
and 796 (21.4%) were older than 80 years. The female patients 
were slightly older (median age, 63 years) than the male 
patients (median age, 60 years). The comorbidity level was 
low for 1,624 (43.6%) patients, moderate for 1,241 (33.3%) 
patients, and high for 862 (23.1%) patients. The frequency 
and proportion of index conditions according to major ICD-10 
groups are presented in Table 2 and Figure 1. A surprisingly 
large proportion (17.9%) of the admitting causes were, rather 
imprecisely, coded as “factors influencing health status and 
contact with health services” (Z00–Z99), of which 84.9% were 
“medical observation and evaluation for suspected diseases and 
  conditions” (Z03). The most frequent single cause of admission 
to the MAU was disease of the respiratory system.
Cumulative mortality
The cumulative mortalities are presented in Table 3 
and   Figures 2–5. The overall unadjusted mortality was 
5.7% after 1 month, 9.5% after 3 months, and 12.8% 
after 6 months (Figure 2). Men had a slightly higher 
adjusted mortality compared with women (Figure 3). 
Patients younger than 65 years had a lower 1-, 3-, and 
6-month adjusted mortality (0.9%, 1.6%, and 2.3%, 
respectively) compared with those aged 65–80 years (6.8%, 
10.7%, and 16.1%, respectively) and with those older than 
80 years (13.2%, 22.3%, and 28.4%, respectively). Simi-
larly, patients with a low comorbidity level had a reduced 
1-, 3-, and 6-month adjusted mortality (1.0%, 1.5%, and 
2.1%, respectively) compared with those with moderate 
comorbidity level (4.2%, 7.2%, and 10.1%, respectively) 
and with those with high comorbidity level (10.8%, 18.6%, 
and 24.8%, respectively).
Table 1 Characteristics of patients with a first-ever admission 
to  the  medical  admission  unit  at  Aarhus  University  hospital, 
nørrebrogade, during 2008
Patients
n %
Overall 3,727 100.0
gender
  Female 1,997 53.6
  Male 1,730 46.4
Age group (y)
  18–64 2,045 54.9
  65–80 886 23.8
 . 80 796 21.4
Charlson comorbiditiesa
  Myocardial infarction 263 7.1
  Congestive heart failure 358 9.6
  Peripheral vascular disease 279 7.5
  Cerebrovascular disease 559 15.0
  Dementia 86 2.3
  Chronic pulmonary disease 661 17.7
  Connective tissue disease 195 5.2
  Ulcer disease 335 9.0
  Mild liver disease 176 4.7
  Diabetes mellitus 531 14.2
  hemiplegia 29 0.8
  Moderate to severe renal disease 137 3.7
  Diabetes with end-organ damage 319 8.6
  Any tumor 472 12.7
  Leukemia 4 0.1
  Lymphoma 26 0.7
  Moderate to severe liver disease 59 1.6
  Metastatic solid tumor 72 1.9
  AiDS 3 0.1
Comorbidity levelb
  Low 1,624 43.6
  Moderate 1,241 33.3
  high 862 23.1
Notes: aAny hospital discharge diagnosis recorded in the Danish national Patients 
registry between 1977 and the index date; bThree levels of comorbidity were defined 
based on Charlson index scores of 0 (low), 1–2 (moderate), and 3 or more (high).Clinical Epidemiology 2010:2 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
198
Schmidt et al
Table 2 Frequency and proportion of primary admission conditions according to major ICD-10 groups
ICD-10 groups Disease categories n %
A00–B99 Certain infectious and parasitic diseases 126 3.4
C00–D48 neoplasms 19 0.5
D50–D89 Diseases of the blood and blood-forming organs and certain disorders involving 
the immune mechanism
51 1.4
E00–E90 Endocrine, nutritional, and metabolic diseases 299 8.0
F00–F99 Mental and behavioral disorders 265 7.1
g00–g99 Diseases of the nervous system 80 2.1
h00–h59 Diseases of the eye and adnexa 3 0.1
h60–h95 Diseases of the ear and mastoid process 5 0.1
i00–i99 Diseases of the circulatory system 245 6.6
J00–J99 Diseases of the respiratory system 575 15.4
K00–K93 Diseases of the digestive system 76 2.0
L00–L99 Diseases of the skin and subcutaneous tissue 33 0.9
M00–M99 Diseases of the musculoskeletal system and connective tissue 117 3.1
n00–n99 Diseases of the genitourinary system 114 3.1
O00–O99 Pregnancy, childbirth, and the puerperium – –
P00–P96 Certain conditions originating in the perinatal period – –
Q00–Q99 Congenital malformations, deformations, and chromosomal abnormalities – –
r00–r99 Symptoms, signs, and abnormal clinical and laboratory findings, not elsewhere classified 522 14.0
S00–T98 injury, poisoning, and certain other consequences of external causes 528 14.2
V01–Y98 External causes of morbidity and mortality 1 0.0
Z00–Z99 Factors influencing health status and contact with health servicesa 668 17.9
Note: aAmong z-categories, 567 (84.9%) were admitted as “medical observation and evaluation for suspected diseases and conditions” (Z03).
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relative mortality
The results from the Cox regression analysis are presented 
in Tables 4 and 5. The overall adjusted HR comparing males 
with females was 1.16 (95% CI, 0.97–1.39). Compared with 
patients younger than 65 years, the adjusted HR was 2.77 
(95% CI, 2.11–3.64) for patients aged 65–80 years and 5.25 
(95% CI, 4.06–6.80) for patients older than 80 years. The 
impact of increasing age on the mortality HR was most evi-
dent among patients with low comorbidity. Compared with 
low comorbidity patients, the adjusted HR was 2.43 (95% CI, 
1.82–3.24) for patients with a moderate comorbidity and 3.87 
(95% CI, 2.91–5.15) for patients with a high comorbidity. 
The impact of comorbidity level on the mortality HR was 
most evident in the youngest group of patients.
Discussion
In this population-based cohort study, age and comorbid-
ity level were important predictors of 1-, 3-, and 6-month 
mortality following acute admission to the MAU at Aarhus 
University Hospital, Nørrebrogade. Furthermore, age and 
comorbidity seemed to modify the effect of each other. 
Thus, the prognostic effect of comorbidity level decreased 
with increasing age, and vice versa. Thus, a high comorbid-
ity level increases mortality rates relatively more in young 
patients than old patients, which may be due to the fact 
that old age itself increases mortality rates substantially. 
Although not substantial, male gender may also be a predic-
tor of mortality.
This feasibility study is the first to examine the 6-month 
mortality after acute admission to a MAU in a Scandinavian 
population-based setting. The design presented has not pre-
viously been described in Denmark for patients admitted 
to a MAU and may therefore be used in future studies on 
the prevalence and course of acute medical diseases and on 
prognostic factors for different outcomes of interest.
Comorbidity was a major prognostic factor in our 
study. Because the population is aging, it is expected that 
an increasing proportion of acutely hospitalized medical 
patients will present with more comorbidity in the future.2 
It is therefore important to identify prognostic comorbid 
conditions associated with acute medical diseases to plan 
health-care needs, evaluate effectiveness of hospital care, and 
prevent posthospital death. To examine whether comorbid 
diseases and index conditions interact with one another to 
increase mortality (beyond their independent effects alone), 
future studies should include a comparison cohort from the 
general population matched on gender and age and calcu-
late the comorbidity level for members of this comparison 
cohort also.
Several issues should be considered when interpreting our 
results. Our population-based design within a tax-supported 
universal health-care system with complete, independently 
and prospectively recorded medical history reduced the risk 
of referral, diagnostic, and information biases.16
The department registration procedure in the DNPR made 
it possible to identify hospital admissions for acute medical 
conditions17 as well as all in-hospital mortality. A limitation 
was that we were not able to include patients with acute 
myocardial infarction or stroke. The fact that 1 in 6 index 
conditions were imprecisely coded as “medical observation 
and evaluation for suspected diseases and conditions” does 
not affect the present study but suggest that some index 
conditions are underreported in the DNPR.
Table  3  Cumulative  mortality  risk  after  1,  3,  and  6  months, 
overall and according to gender, age, and comorbidity groups
Cumulative mortality (%)
Unadjusted Adjusteda
1 mo 3 mo 6 mo 1 mo 3 mo 6 mo
Overall 5.7 9.5 12.8 3.1 5.3 7.4
gender
  Female 5.4 9.5 12.9 2.8 5.1 7.1
  Male 6.0 9.4 12.7 3.4 5.5 7.7
Age group (y)
  18–64 1.7 3.1 4.4 0.9 1.6 2.3
  65–80 7.3 11.6 17.2 6.8 10.7 16.1
  .80 13.9 23.4 29.4 13.2 22.3 28.4
Comorbidity levelb
  Low 2.0 3.0 4.2 1.0 1.5 2.1
  Moderate 6.3 10.6 14.5 4.2 7.2 10.1
  high 11.7 20.1 26.5 10.8 18.6 24.8
Notes: aAdjusted for gender, age as continuous variable, and comorbidity level (2 in 
each analysis); bThree levels of comorbidity were defined based on Charlson index 
scores of 0 (low), 1–2 (moderate), and 3 or more (high).
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It is possible that confounding by unmeasured variables, 
such as former or current use of tobacco, alcohol, and medica-
tions, and biochemical markers, influenced our results. Future 
studies should, if possible, include such variables18,19 and 
furthermore differentiate between index conditions because 
risk factors, prognostic factors, and survival probabilities 
vary among these conditions. Comparing mortality following 
acute medical conditions for different time periods may also 
add evidence on the effectiveness of newer treatment regi-
mens. Moreover, comparing whether short-term or long-term 
mortality depends on the admission time during the day and 
week may challenge the internal organization of health-care 
systems. Other important outcome measures include length of 
stay, hospital acquired infections, venous thromboembolism, 
readmission rates, cause-specific   mortality, and in-hospital 
mortality.
In conclusion, age and comorbidity were important 
  predictors of mortality after acute medical admission.
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Table 5 Mortality hazard ratios stratified on gender, age, and 
comorbidity groups
Hazard ratios  
(95% confidence intervals)
Unadjusted Adjusteda
Female patients
  Age 65–80 4.74 (3.20–7.03) 2.93 (1.95–4.41)
  Age .80 8.73 (6.08–12.53) 5.26 (3.60–7.68)
  Moderate comorbidity 4.38 (2.94–6.51) 2.79 (1.86–4.21)
  high comorbidity 8.98 (6.09–13.25) 4.74 (3.15–7.13)
Male patients
  Age 65–80 3.77 (2.65–5.34) 2.68 (1.86–3.86)
  Age .80 7.56 (5.38–10.63) 5.35 (3.74–7.65)
  Moderate comorbidity 3.02 (2.03–4.47) 2.11 (1.41–3.16)
  high comorbidity 5.61 (3.84–8.20) 3.11 (2.08–4.65)
Patients aged 18–64 y
  Male 1.18 (0.78–1.80) 1.12 (0.74–1.71)
  Moderate comorbidity 2.12 (1.22–3.67) 2.10 (1.21–3.65)
  high comorbidity 4.65 (2.68–8.09) 4.62 (2.66–8.03)
Patients aged 65–80 y
  Male 1.16 (0.84–1.59) 1.09 (0.79–1.50)
  Moderate comorbidity 1.59 (0.95–2.68) 1.58 (0.94–2.66)
  high comorbidity 2.79 (1.71–4.56) 2.76 (1.69–4.52)
Patients aged $80 y
  Male 1.27 (0.98–1.66) 1.24 (0.95–1.61)
  Moderate comorbidity 2.19 (1.42–3.37) 2.20 (1.43–3.39)
  high comorbidity 2.89 (1.88–4.43) 2.85 (1.86–4.37)
Patients with low comorbidityb
  Male 1.35 (0.84–2.18) 1.70 (1.05–2.74)
  Age 65–80 5.38 (2.93–9.85) 5.55 (3.03–10.18)
  Age .80 9.05 (5.13–15.96) 9.83 (5.54–17.44)
Patients with moderate comorbidityb
  Male 0.94 (0.70–1.26) 1.24 (0.92–1.68)
  Age 65–80 2.81 (1.81–4.37) 2.83 (1.82–4.40)
  Age .80 6.22 (4.17–9.28) 6.54 (4.36–9.81)
Patients with high comorbidityb
  Male 0.85 (0.66–1.10) 0.98 (0.75–1.27)
  Age 65–80 1.70 (1.15–2.51) 1.69 (1.14–2.51)
  Age .80 2.82 (1.94–4.11) 2.81 (1.92–4.11)
Notes: The reference groups (not shown) were female patients, patients aged 18–
64 years, and patients with low comorbidity.
aThe  adjustments  differed  between  strata  and  included  only  the  nonstratifying 
variable (either gender, age as a continuous variable, or comorbidity level). As an 
exception for age strata, additional adjustment for age as a continuous variable was 
made; bThree levels of comorbidity were defined based on Charlson index scores of 
0 (low), 1–2 (moderate), and 3 or more (high).
Table  4  Mortality  hazard  ratios  within  gender,  age,  and 
comorbidity groups
Hazard ratios  
(95% confidence intervals)
Unadjusted Adjusteda
gender
  Female 1.00 (reference) 1.00 (reference)
  Male 0.99 (0.82–1.18) 1.16 (0.97–1.39)
Age group (y)
  18–64 1.00 (reference) 1.00 (reference)
  65–80 4.16 (3.20–5.39) 2.77 (2.11–3.64)
  .80 7.76 (6.08–9.90) 5.25 (4.06–6.80)
Comorbidity levelb
  Low 1.00 (reference) 1.00 (reference)
  Moderate 3.65 (2.76–4.83) 2.43 (1.82–3.24)
  high 7.15 (5.45–9.37) 3.87 (2.91–5.15)
Notes: aAdjusted for gender, age as a continuous variable, and comorbidity level (2 
in each analysis). bThree levels of comorbidity were defined based on Charlson index 
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Appendix
ICD codes for Charlson comorbidity 
index
Myocardial infarction: ICD-8: 410; ICD-10: I21, I22, I23.
Congestive heart failure: ICD-8: 427.09, 427.10, 427.11, 
427.19, 428.99, 782.49; ICD-10: I50, I11.0, I13.0, I13.2.
Peripheral vascular disease: ICD-8: 440, 441, 442, 443, 444, 
445; ICD-10: I70, I71, I72, I73, I74, I77.
Cerebrovascular disease: ICD-8: 430–438; ICD-10: I60–I69, 
G45, G46.
Dementia: ICD-8: 290.09–290.19, 293.09; ICD-10: F00–
F03, F05.1, G30.
Chronic pulmonary disease: ICD-8: 490–493, 515–518; 
ICD-10: J40–J47, J60–J67, J68.4, J70.1, J70.3, J84.1, J92.0, 
J96.1, J98.2, J98.3.
Connective tissue disease: ICD-8: 712, 716, 734, 446, 135.99; 
ICD-10: M05, M06, M08, M09, M30, M31, M32, M33, 
M34, M35, M36, D86.
Ulcer disease: ICD-8: 530.91, 530.98, 531–534; ICD-10: 
K22.1, K25–K28.
Mild liver disease: ICD-8: 571, 573.01, 573.04; ICD-10: B18, 
K70.0–K70.3, K70.9, K71, K73, K74, K76.0.
Diabetes mellitus: ICD-8: 249.00, 249.06, 249.07, 249.09, 
250.00, 250.06, 250.07, 250.09; ICD-10: E10.0, E10.1, 
E10.9, E11.0, E11.1, E11.9.
Hemiplegia: ICD-8: 344; ICD-10: G81, G82.
Moderate to severe renal disease: ICD-8: 403, 404, 580–583, 
584, 590.09, 593.19, 753.10–753.19, 792; ICD-10: I12, I13, 
N00–N05, N07, N11, N14, N17–N19, Q61.
Diabetes with end-organ damage: ICD-8: 249.01–249.05, 
249.08, 250.01–250.05, 250.08; ICD-10: E10.2–E10.8, 
E11.2–E11.8.
Any tumor: ICD-8: 140–194; ICD-10: C00–C75.
Leukemia: ICD-8: 204–207; ICD-10: C91–C95.
Lymphoma: ICD-8: 200–203, 275.59; ICD-10: C81–C85, 
C88, C90, C96.
Moderate to severe liver disease: ICD-8: 070.00, 070.02, 
070.04, 070.06, 070.08, 573.00, 456.00–456.09; ICD-10: 
B15.0, B16.0, B16.2, B19.0, K70.4, K72, K76.6, I85;
Metastatic solid tumor: ICD-8: 195–198, 199; ICD-10: 
C76–C80.
AIDS: ICD-8: 079.83; ICD-10: B21–B24.